Kirkland & Ellis advised Warburg Pincus on its investment in Polyplus-transfection® SA (“Polyplus”), a developer of innovative and cost-effective technology used in gene and cell therapy. Warburg Pincus’ investment alongside the existing majority shareholder, European private equity healthcare specialist ArchiMed, will advance the development and sale of Polyplus’ breakthrough solutions for the delivery of nucleic acids (transfection) for research and the biologics-based production of therapeutic drugs and vaccines.
ArchiMed and Warburg Pincus will be equal shareholders with the same voting rights. Their partnership will enable Polyplus to access the combined resources of both firms and better serve customers. Polyplus’ management team will continue to be significant minority shareholders.
The Kirkland team was led by transactional partners Laurent Victor-Michel in Paris and Adrian Maguire in London; debt finance partners Neel Sachdev and Leon Daoud in London and Eric Wedel in New York and tax partner Nadine Gelli in Paris. The team was supported by transactional associates Guillaume Nivault (Paris) and Dan Clarke (London).